AKH: A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration - EASL SLD Summit 2025
View
Metabolism, Alcohol & Toxicity
5
AKH: A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration - EASL SLD Summit 2025
View
Metabolism, Alcohol & Toxicity
5
AKH: A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration - EASL SLD Summit 2025
View
Metabolism, Alcohol & Toxicity
5
AKH: A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration - EASL SLD Summit 2025
View
Metabolism, Alcohol & Toxicity
5
AKH: A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration - EASL SLD Summit 2025
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
